Literature DB >> 20100068

Preparation, in vitro characterization, pharmacokinetic, and pharmacodynamic evaluation of chitosan-based plumbagin microspheres in mice bearing B16F1 melanoma.

Sunil Kumar Mandala Rayabandla1, Kiran Aithal, Aravind Anandam, Gopal Shavi, Udupa Nayanabhirama, Karthik Arumugam, Prashant Musmade, Krishnamoorthy Bhat, Satish Rao Bola Sadashiva.   

Abstract

The present study was aimed to evaluate the anti-tumor efficacy and systemic toxicity of chitosan-based plumbagin microspheres in comparison to free plumbagin. The optimized formulation had a mean particle size of 106.35 mum with an encapsulation efficiency of 80.12%. Pharmacokinetic studies showed a 22.2-fold increase in elimination half-life (t(1/2)) of plumbagin from chitosan microspheres as compared to free plumbagin. Administration of plumbagin microspheres resulted in a significant tumor growth inhibition and reduced systemic toxicity. These results suggest that chitosan-based microspheres could be a promising strategy for the systemic delivery of anti-cancer agents like plumbagin.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20100068     DOI: 10.3109/10717540903548447

Source DB:  PubMed          Journal:  Drug Deliv        ISSN: 1071-7544            Impact factor:   6.419


  5 in total

1.  Sustained release optimized formulation of anastrozole-loaded chitosan microspheres: in vitro and in vivo evaluation.

Authors:  Gopal V Shavi; Usha Y Nayak; M Sreenivasa Reddy; A Karthik; Praful B Deshpande; A Ranjith Kumar; N Udupa
Journal:  J Mater Sci Mater Med       Date:  2011-03-23       Impact factor: 3.896

2.  Brain targeted oral delivery of doxycycline hydrochloride encapsulated Tween 80 coated chitosan nanoparticles against ketamine induced psychosis: behavioral, biochemical, neurochemical and histological alterations in mice.

Authors:  Monu Yadav; Milind Parle; Nidhi Sharma; Sameer Dhingra; Neha Raina; Deepak Kumar Jindal
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

3.  Pharmacokinetics, toxicity, and cytochrome P450 modulatory activity of plumbagin.

Authors:  Wiriyaporn Sumsakul; Tullayakorn Plengsuriyakarn; Kesara Na-Bangchang
Journal:  BMC Pharmacol Toxicol       Date:  2016-11-14       Impact factor: 2.483

4.  Regression of Melanoma Following Intravenous Injection of Plumbagin Entrapped in Transferrin-Conjugated, Lipid-Polymer Hybrid Nanoparticles.

Authors:  Intouch Sakpakdeejaroen; Sukrut Somani; Partha Laskar; Margaret Mullin; Christine Dufès
Journal:  Int J Nanomedicine       Date:  2021-04-06

5.  Propylene Glycol Caprylate-Based Nanoemulsion Formulation of Plumbagin: Development and Characterization of Anticancer Activity.

Authors:  Adrian Chrastina; John Welsh; Per Borgström; Veronique T Baron
Journal:  Biomed Res Int       Date:  2022-01-10       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.